鼻喷新冠疫苗临床试验
Nasal COVID vaccine in trials
香港大学9月9日宣布，该校微生物学系与内地机构联合研发的鼻喷新冠疫苗已获批开展临床试验。
The University of Hong Kong said on Wednesday the clinical trials of a nasal spray vaccine for COVID-19, jointly developed by the university's department of microbiology and mainland institutions, have been approved.
这款疫苗由港大新发传染病国家重点实验室与厦门大学、北京万泰生物药业股份有限公司共同研发，是首款通过国家药品监督管理局审批，获准开展人体临床试验的鼻喷式新冠疫苗。
The State Key Laboratory of Emerging Infectious Diseases has been working on the vaccine with Xiamen University and Beijing Wantai Biological Pharmacy. It is the first nasal spray COVID-19 vaccine approved by China's National Medical Products Administration for clinical trials in humans.
港大在声明中称，这个疫苗研究项目得到科技部立项支持，是国家五个重点疫苗技术策略之一。
HKU said in a statement its vaccine strategy has been selected as one of five vaccine technologies by the Ministry of Science and Technology for further evaluation.